



REVIEW

Recent advances in allergic rhinitis [version 1; referees: 2 approved]

Flavia C. L. Hoyte , Harold S. Nelson

Department of Medicine, Division of Allergy/Immunology, National Jewish Health, Denver, CO, 80206, USA

v1 **First published:** 23 Aug 2018, 7(F1000 Faculty Rev):1333 (doi: 10.12688/f1000research.15367.1)
Latest published: 23 Aug 2018, 7(F1000 Faculty Rev):1333 (doi: 10.12688/f1000research.15367.1)

Abstract

Allergic rhinitis affects 20 to 30% of adults in both the United States and Europe and perhaps a somewhat higher percentage of children. In addition to nasal and ocular symptoms directly related to the allergic process, interference of these symptoms with sleep leads to daytime sleepiness and impaired quality of life. Patients miss work because of symptoms but an even greater problem is interference with work productivity, or presenteeism, which has been reported to be the biggest contributor to the total economic cost of allergic rhinitis. There has been increasing awareness that many patients with either seasonal or perennial symptoms but negative skin and *in vitro* tests for allergen sensitivity have local nasal allergy, diagnosable by the presence of allergen-specific IgE in their nasal secretions or a positive nasal allergen challenge or both. The pharmaceutical management of allergic rhinitis rests on symptomatic treatment with antihistamines that perhaps are more effectively administered intranasally than orally and intranasal corticosteroids. Allergen immunotherapy is very effective, even for local allergic rhinitis, and the shortcomings of subcutaneous immunotherapy of inconvenience and safety are reduced by the introduction of sublingual immunotherapy (SLIT). Use of the latter is currently somewhat limited by the lack of appropriate dosing information for SLIT liquids and the limited number of allergens for which SLIT tablets are available.

Keywords

Allergic Rhinitis, Local nasal allergy, Immunotherapy, SCIT, SLIT

Open Peer Review

Referee Status:  

	Invited Referees	
	1	2
version 1 published 23 Aug 2018		

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **Miguel Blanca**, Regional University Hospital of Malaga, Spain
- 2 **Cemal Cingi**, Eskisehir Osmangazi University, Turkey

Discuss this article

Comments (0)

Corresponding author: Flavia C. L. Hoyte (hoytef@njhealth.org)

Author roles: Hoyte FCL: Writing – Original Draft Preparation, Writing – Review & Editing; Nelson HS: Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: HSN has received honoraria from ALK-Abelló for speaking and consulting. He was previously a consultant to Merck. FH declares that she has no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Hoyte FCL and Nelson HS. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Hoyte FCL and Nelson HS. **Recent advances in allergic rhinitis [version 1; referees: 2 approved]** *F1000Research* 2018, 7(F1000 Faculty Rev):1333 (doi: [10.12688/f1000research.15367.1](https://doi.org/10.12688/f1000research.15367.1))

First published: 23 Aug 2018, 7(F1000 Faculty Rev):1333 (doi: [10.12688/f1000research.15367.1](https://doi.org/10.12688/f1000research.15367.1))

Introduction

Allergic rhinitis (AR) is a common condition. Estimates of its prevalence vary widely but good epidemiologic studies suggest that 20 to 30% of adults and up to 40% of children are affected¹. Symptoms can have significant negative impact on the patients' quality of life, often interfere with sleep, and contribute to poor performance at work and school. In approaching the patient with rhinitis symptoms, clinicians must distinguish AR from non-AR (NAR) and nasal symptoms due to mechanical factors but not miss the presence of local nasal allergy. Treatment for more severe disease should employ anti-inflammatory as well as symptomatic medication, and allergy immunotherapy (AIT) should be strongly considered for not only its effectiveness but also its disease-modifying effects. The main challenges in AR relate to its treatment. Symptomatic and topical anti-inflammatory medication is often not fully effective, and AIT can be inconvenient and expensive, and there is much room for improvement in both forms of treatment.

The burden of allergic rhinitis

In 2004, a mail survey in the US elicited responses from two thirds contacted². Of 19,678 adult responders, 44.3% reported nasal symptoms on at least seven days per year, 30.2% attributed these symptoms to allergies, and 20.7% reported a physician diagnosis of nasal allergies. In 2001, a two-step survey was conducted in Belgium, France, Germany, Italy, Spain, and the UK³. A questionnaire was administered by telephone to 9646 adults to determine the presence of a diagnosis of or symptoms suggestive of AR. Self-awareness of AR was reported by 19%, and 13% reported a physician diagnosis of AR. All of those with positive responses were invited to a clinical center for definitive diagnosis and 725 were examined. On clinical examination, 411 out of 725 were diagnosed as having AR; 45% of these 411 had not received a previous physician diagnosis. This led to estimates of clinically confirmable AR varying from 17% in Italy to 29% in Belgium and overall 23% for the European population studied. The incidence and prevalence of AR in the children were studied in an Isle of Wight birth cohort (n = 1456) recruited in 1989⁴. Prevalence of AR increased from 3.4% at 4 years of age to 27.3% at 18 years and was more common in boys than girls at that age.

In a telephone survey of 2765 adults and children (at least five years old) with a diagnosis of nasal or ocular allergies or both, 78% reported seasonal symptoms, and the peak was during the tree season (March to May) and a lesser peak occurred in the fall weed season (September)⁵. At the peak of their or their child's allergy season, 39% rated nasal congestion and 34% red itchy eyes as "extremely bothersome" whereas 29% said daily life was "impaired a lot"⁵.

The symptoms of AR interfere with the ability to sleep, leading to daytime sleepiness and impaired quality of life⁶. In a survey of 100 patients who had moderate/severe AR, sleep disturbances were reported by 66% of adults and 43% of children⁷. Patients with moderate/severe AR, compared with

those with mild disease, had significantly more anxiety, depression, fatigue, trouble with social interactions, and perceived signs of cognitive dysfunction⁷. The disturbances of sleep extend to parents of children with AR, 75% of whom reported poor-quality sleep⁸.

A Medline search retrieved original studies from 2005 to 2015 on the impact of AR on work productivity⁹. Pooled analysis of studies in which the validated Work Productivity and Activity Impairment (WPAI) questionnaire had been used to collect data found an estimated 3.6% of missed work time (absenteeism) and 35.9% of work performance impairment (presenteeism) due to AR. The cost of absenteeism and presenteeism was estimated to be 3.2- to 13.5-fold higher than direct medical costs and to represent 76 to 93% of the total costs of AR⁹. School performance is also affected by AR. In a case control study in the UK, students who were 15 to 17 years of age and currently symptomatic with AR were significantly more apt to have lower examination scores in the summer compared with the winter¹⁰. The cost of AR was assessed in a representative sample of the Swedish population (18 to 65 years of age) in a report published in 2016¹¹. The mean annual direct and indirect costs because of AR were 210 Euros and 750.8 Euros, respectively. Of the total cost, 8.1% was due to absenteeism and 70.0% was due to presenteeism. The remainder was equally divided between pharmaceutical and health-care costs¹¹. The cost for the European Union countries for absenteeism and presenteeism caused by AR in untreated or inadequately treated individuals has been estimated at 55 to 151 million Euros per year¹².

The impact of climate change on allergic rhinitis

The potential effect of climate change on the severity and extent of AR has been examined, most intensively in the case of ragweed pollen¹³⁻¹⁵. Increasing temperature and carbon dioxide exposure have been shown to increase the production of pollen from individual plants¹³. At the same time, the increase in the number of frost-free days and the later occurrence of the first frost have been shown to correlate with longer ragweed pollen seasons and are predicted to allow ragweed to propagate further north¹⁴. This is of special concern in Europe, where ragweed is established in the Rhone Valley/Burgundy in France, northern Italy, Hungary, and surrounding countries¹⁵. Thus, with favorable climatic conditions, it is poised to extend into Poland, Germany, and northern France¹⁵.

Rhinitis subtypes

The first step in rhinitis management is determining the type(s) of rhinitis that an individual has and this can be complicated given the various phenotypes and endotypes of rhinitis. A phenotype is defined by clinical presentation, whereas an endotype is defined by underlying pathophysiologic mechanism. AR is generally differentiated from NAR by the presence of positive allergy skin testing or serum-specific IgE testing. As discussed below, there has been an increasing interest recently in local AR (LAR), which is generally diagnosed in individuals with negative serum and skin allergy tests but

histories suggestive of AR, through a positive nasal allergen challenge or the identification of specific IgE (sIgE) in nasal secretions or both¹⁶.

NAR has many subtypes, including infectious, drug-induced, gustatory, hormone-induced, atrophic, senile, and idiopathic rhinitis (IR)¹⁷. Nasal symptoms can also occur as a result of structural or mechanical issues, such as choanal atresia, adenoidal hypertrophy, septal deviation, nasal tumors, or cerebrospinal fluid leaks, as well as systemic conditions, such as cystic fibrosis, primary ciliary dyskinesia, eosinophilic granulomatosis and polyangiitis, sarcoidosis, and amyloidosis. Occupational rhinitis, which can be either allergic or non-allergic, has many causative agents and can present either shortly after starting an occupation with a new antigenic exposure or following a latency period, when an individual is developing sensitization to the new antigen. Oftentimes, patients have more than one type of rhinitis, leading to a mixed phenotype or endotype or both^{16,18}.

Natural history of allergic rhinitis

The natural history of AR seems to be different from that of NAR¹⁹. Young children with NAR are more likely to go into remission than their AR counterparts. In a birth cohort of over 2000 children, 73% of NAR subjects and only 12% of AR subjects went into remission between ages 4 and 8. The proportion of children with NAR decreased slightly from age 4 (8%) to age 8 (6%), whereas AR rates increased between these ages from 5% to 14%. Sensitization often precedes AR as over half of those who were sensitized but asymptomatic at age 4 developed AR by age 8¹⁹. In a questionnaire-based study of adults who were 20 to 59 years old, about 23% of cases demonstrated remission of their AR symptoms within an eight-year period from 1992 to 2000, and the highest rate of remission was in the oldest age group (50 to 59 years) and the lowest rate of remission was in those with concomitant asthma. The highest incidence of new-onset AR was seen in the youngest age group (20 to 29 years)²⁰.

ARIA (Allergic Rhinitis and its Impact on Asthma), the World Health Organization initiative on AR, published guidelines in 2001 that shifted the paradigm from classifying AR as either seasonal AR (SAR) or perennial AR (PAR) to a classification based on frequency (persistent or intermittent, as defined below) and severity (mild or moderate/severe, based on whether or not there is impaired sleep, impairment of daily life, or troublesome symptoms)²¹. They defined intermittent AR as affecting patients less than four days a week or less than four consecutive weeks, whereas symptoms in persistent AR lasted more than four days a week or more than four consecutive weeks²¹. Since their initial publication, these guidelines have been updated and refined multiple times^{22–24}.

Based on a study from Western Europe in which telephone interviews were performed on 9646 individuals, 726 of whom came to the clinical center for an evaluation, the investigators found a poor correlation between the

seasonal/perennial terms and the intermittent/persistent classifications, respectively, and about half of the persistent subjects had SAR and half of the intermittent subjects had PAR². Another study, by Ciprandi *et al.*, demonstrated that 80% of patients with AR have a mixed form of SAR and PAR, suggesting to the authors that the terms PAR and SAR are poorly reflective of real life and that intermittent and persistent may be more applicable²⁵.

Local allergic rhinitis

In the last decade and a half, there has been increasing interest (particularly by a group led by Miguel Blanca in Malaga, Spain) in LAR, a term applied to patients whose allergy skin and blood testing is negative but who have a history suggestive of allergic sensitization and local evidence of atopy diagnosed by sIgE in nasal secretions or by positive nasal allergen challenge or both.

In a study of 50 patients with perennial NAR (PNAR), 30 with PAR, and 30 healthy controls, Rondón *et al.* found a similar nasal leukocyte-lymphocyte phenotype in the nasal lavage of PAR and PNAR patients, both of which differed from normal controls, who tended to have fewer eosinophils, total lymphocytes, and CD3⁺CD4⁺ lymphocytes²⁶. A positive nasal challenge with *Dermatophagoides pteronyssinus* (D. pt.) was present in 54% of the patients with PNAR, and sIgE was identified in 22% of these individuals²⁶. In another study, in which 40 patients with LAR due to D. pt. underwent nasal challenge with D. pt., 60% had isolated and 40% had dual positive responses²⁷. Tryptase was present in the nasal secretions of 45%, elevated eosinophil chemotactic factor in 65%, and D. pt.-specific IgE in 25%. LAR to pollens has also been demonstrated by this group in a similar study comparing individuals with seasonal IR with those with pollen-induced AR. This study found similar nasal leukocyte-lymphocyte profiles in both sets of rhinitis patients, which were different from that of controls. Of the subjects with IR, 62.5% had a positive nasal allergen provocation test (NAPT) and 35% demonstrated nasal sIgE²⁸. Rondón, *et al.* also have investigated multiple NAPT (NAPT-M), in which four different allergen extracts are administered at 15-minute intervals, and have demonstrated 100% concordance with single-aeroallergen NAPTs, suggesting that this may be an efficient and cost-effective way to detect polysensitization in patients with LAR²⁹.

A study to determine the prevalence of LAR in a Spanish population evaluated 452 unselected adult patients with rhinitis by means of skin-prick tests, sIgE, and NAPT; they diagnosed LAR in 25.7%, AR in 63.1%, and NAR in 11.2%³⁰. A study evaluating LAR to house dust mites (HDMs), specifically evaluating a pediatric population with NAR (mean age of 11 years and median disease duration of 6.3 years), used nasal tryptase, symptoms, physiologic measures (peak nasal inspiratory flow and acoustic rhinometry), and local production of HDM-sIgE and demonstrated that LAR to HDM is rare in children. Only two (3.7%) of the 54 children showed significant change in symptoms and physiologic measures

following HDM-NAPT³¹. In contrast, a study by Bozek *et al.* looking at an elderly population (mean age of 65.81, n = 219) with undiagnosed persistent rhinitis demonstrated a rate of LAR of 21%, and D. pt. was the main sensitizing aeroallergen in those with LAR (63%)³². In this study, symptom changes during NAPT were accompanied by an increase in nasal sIgE. The large, questionnaire-based studies conducted to determine the prevalence of AR in the general population could not assess the prevalence of LAR since nasal allergen challenges were not part of the protocol^{2,3}.

A five-year follow-up study in 194 patients with LAR demonstrated worsening in 26.3% of the patients, and the development of atopy at five years was detected by skin-prick test or sIgE (or both) in 6.81% of LAR and 4.5% of normal control patients³³. At 10 years, the rate of development of systemic atopy was similar in the LAR patients and controls (9.7% versus 7.8%, $P = 0.623$). This indicates that LAR is usually a persistent condition and not a precursor to AR. The patients with LAR in this study demonstrated a significant worsening of their rhinitis over time and this was clinically relevant and associated with development of asthma³⁴. Treatment of LAR with immunotherapy is discussed in the section on immunotherapy, below.

Management of allergic rhinitis

Management of AR continues to revolve around allergen avoidance, medications that provide symptomatic relief, anti-inflammatory therapies, and AIT. Recent advances in therapy include intranasal antihistamines and novel methods of delivery for intranasal steroids, which continue to be the mainstay of therapy for AR and now can be found over-the-counter in the US for some formulations.

Intranasal antihistamines, introduced in the US in 2000^{35,36}, have broadened the landscape of intranasal medications for the treatment of AR. They have been shown to improve the total nasal symptom score (TNSS) as well as each individual nasal symptom score (INSS) for sneezing, rhinorrhea, nasal congestion, and nasal itching with faster onset and similar efficacy when compared with intranasal steroids³⁷. Intranasal antihistamines also have a faster onset than oral antihistamines and can improve all INSSs to a similar degree, except for nasal congestion, which is better controlled by nasal compared with oral antihistamines³⁸.

Novel delivery methods of intranasal steroids include a nasal preparation of ciclesonide, a steroid pro-drug that is converted to its active form only upon tissue delivery, introduced in aqueous form in the US in 2006³⁹; a mist formulation of fluticasone furoate, approved by the US Food and Drug Administration (FDA) in 2007⁴⁰; and aerosol devices using hydrofluoroalkane (HFA) propellant to deliver beclomethasone⁴¹ and ciclesonide⁴², both approved by the FDA in 2012. The newest delivery mechanism for intranasal therapy is an exhalation-activated device, which currently (2017) is approved only for the delivery of fluticasone propionate to treat nasal polyps⁴³

but which eventually might be approved for the treatment of AR.

In 2012, a combination spray containing both fluticasone propionate and azelastine hydrochloride was approved by the FDA⁴⁴. Aggregate data from 3398 subjects in three multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group trials demonstrated a faster onset and superior efficacy as compared with each of the individual components. The onset of action was 30 minutes, and clinical improvement was observed during the first day of assessment and there was sustained benefit for the entire two-week study period⁴⁵. An updated consensus treatment algorithm proposes an approach to treatment that is in keeping with the ARIA guidelines and highlights a more prominent role for nasal antihistamines⁴⁶.

Although there has been a recent increase in interest among the general population regarding complementary and alternative medicine (CAM) approaches, including acupuncture, traditional Chinese medicine, and homeopathy, there is a paucity of randomized controlled studies evaluating these approaches. Acupuncture has the greatest amount of data and shows promise in smaller randomized studies⁴⁷⁻⁵⁰. Several review articles have been published on the topic of CAM and its role in treating allergic disease, including AR⁵¹⁻⁵³. The consensus among these articles is that although CAM is considered to be low-risk and to have potential benefit, additional studies are needed to fully evaluate the efficacy and potential long-term benefit of these therapies⁵¹⁻⁵³.

Efficacy of subcutaneous and sublingual immunotherapy in allergic rhinitis

A number of systematic reviews (SRs) of subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) (or both) for AR have been conducted. A committee of the European Academy of Allergy and Clinical Immunology critically assessed these SRs for evidence of the effectiveness, safety, and cost-effectiveness of AIT for allergic rhinoconjunctivitis (ARC)⁵⁴. They identified 17 SRs published through the end of October 2015. These SRs suggested that, in carefully selected patients, SCIT and SLIT resulted in significant reductions in symptom scores and medication requirements for ARC with reassuring safety data. The data could not support conclusions on the relative clinical effectiveness or the cost-effectiveness of the two approaches to AIT.

The major recent development in AIT in the US for ARC has been the introduction of SLIT tablets containing Timothy grass, a five-grass mixture, short ragweed, or HDM (D. pt. and *Dermatophagoides farinae*) extracts. The doses of the five tablets chosen for commercial development, expressed as the content of major allergen, are listed in Table 1. In most, a dose-ranging study has been performed that identified an effective dose as well as one or more less effective doses⁵⁵⁻⁵⁹. In the case of ragweed and HDMs, there were also studies that suggested that doses higher than those eventually approved carried safety concerns^{60,61}.

Table 1. Major allergen content of sublingual immunotherapy tablets selected for commercial development.

Author	Allergen extract	Major allergen content	Clinical effect versus placebo
Durham <i>et al.</i> ⁵⁵ (2006)	Timothy	75,000 SQ = 17 µg Phl p 5	Symptoms 21% ^a Medications 29% ^a
Didier <i>et al.</i> ⁵⁶ (2007)	Five grasses (orchard, meadow, perennial rye, sweet vernal, and Timothy)	300 IR = 25 µg group 5 allergen	RTSS 300 IR 37% 500 IR 35%
Nolte <i>et al.</i> ⁵⁷ (2013) Creticos <i>et al.</i> ⁵⁸ (2013)	Short ragweed	12 Amb a 1-U = 12 µg Amb a 1	TCS Peak ragweed season: 27% and 24%
Demoly <i>et al.</i> ⁵⁹ Nolte <i>et al.</i> ⁵²	House dust mites	12 DU = 7.5 µg each of Der p 1, Der f 1, Der p 2, and Der f 2	6 DU – TCS 17.3% 12 DU – TCS 17.7% 12 DU – TCS 17%
Bergmann <i>et al.</i> ⁶³ (2014) Okamoto <i>et al.</i> ⁶⁴ (2016)	House dust mites	300 IR = 16 µg Der p 1+ 68 µg Der f 1	AAdSS 300 IR – 17.9% 500 IR – 20.2% AASS 300 IR – 18.2% 500 IR – 13.1%

^aSubjects who completed at least eight weeks of treatment before the grass pollen season. AAdSS, average adjusted symptom score (symptom score adjusted for medication use); AASS, average adjusted symptom score (adjusted for medication use); DU, developmental units; IR, index of reactivity; RTSS, rhinoconjunctivitis total symptom score; SQ, standardized quality; TCS, total combined score.

The safety data in these phase III studies of SLIT tablets have been reassuring, and no fatal or life-threatening adverse reactions have been reported^{55–59,64}. The use of epinephrine to treat SLIT tablet-related adverse events (TRAEs) was reported for 29 studies conducted for the registration of the ALK Timothy, short ragweed, and HDM SLIT tablets⁶⁵. Epinephrine was administered to treat 16 TRAEs: six systemic and 10 local application site reactions. Of the six systemic reactions, none were considered serious, five occurred with the first administration under physician observation, and one occurred on the sixth day of treatment. The occurrence of adverse reactions to short ragweed SLIT tablet was tabulated for the first 28 days of four safety or efficacy studies (or both) conducted for registration of the product⁶⁶. Local application site reactions were common but usually mild-moderate, of brief duration, and occurring mostly in the first week or two of treatment.

Five-year studies were conducted with both the Timothy⁶⁷ and the five-grass⁶⁸ SLIT tablets, in which treatment administered either continuously⁶⁷ or pre- and co-seasonally⁶⁸ was continued for three years, and the subjects were followed for two years after cessation of treatment to determine whether there was persisting benefit. With the Timothy tablet, there was 36% improvement compared to placebo in the symptom/medication score during the third year of treatment and persisting improvement of 34% and 27% the two follow-up years⁶⁷. With the five-grass SLIT tablet, the improvement in the symptom/medication score during the third year of treatment was 39%, and that the two follow-up years was 30% and 28%⁶⁸. Both results suggest that there has been modification

of the underlying immunologic process by the immunotherapy. On the other hand, a study with the same dose of Timothy SLIT tablet, administered daily but for only two years, produced a clinical response that was lost one year after treatment discontinuation, suggesting that treatment of at least three years was required to produce persisting improvement⁶⁹.

Further evidence of disease modification by AIT comes from the results of a phase IV study with the Timothy grass SLIT tablet that examined the effect of three years of treatment of children ages 5 to 12 years who had documented grass-induced AR but no evidence of pre-existing asthma on careful screening⁷⁰. In the 812 children, three years of treatment produced persisting improvement in clinical AR during two years of follow-up. More importantly, the development of both summertime and wintertime asthma was significantly reduced in the group that had received the Timothy SLIT tablets when compared with those who had received placebo treatment (Table 2). This suggests, for the first time, that immunotherapy may protect against the development of asthma caused by factors beyond the allergen used in treatment.

Use of SLIT with liquid preparations in the US has been limited by the lack of an FDA-approved allergen extract for SLIT, although there is some “off label” use^{71,72}. In Europe, SLIT with liquid preparations is widely employed. However, studies of extracts from three major European extract manufacturers suggested widely varying doses, some of which are well below those that have proven to be necessary for clinical efficacy in dose-ranging studies of SLIT tablets⁷³.

Table 2. Reduction in the incidence of asthma in children treated 3 years with Timothy grass SLIT tablets with 2-year follow-up⁷⁰.

	Year 1	Year 2	Year 3	Year 4	Year 5
Summer visits					
SQ grass versus placebo SLIT tablet	OR = 0.57 P = 0.067	OR = 0.40 P = 0.0014	OR = 0.54 P = 0.048	OR = 0.37 P = 0.00064	OR = -0.55 P = 0.042
Winter visits					
SQ grass versus placebo SLIT tablet	OR = 1.69 P = 0.13	OR = 1.22 P = 0.53	OR = 0.54 P = 0.059	OR = 0.44 P = 0.016	OR = 0.37 P = 0.0027

OR, odds risk; SLIT, sublingual immunotherapy; SQ, standardized quality.

The same marked heterogeneity of dosing was found in a study of five commercial HDM liquid SLIT preparations in Spain⁷⁴. The ranges in doses recommended by the five companies were 130-fold for Der p 1, 129-fold for Der f 1, and 115-fold for group 2 allergens. An additional problem with the use of SLIT liquid extracts in the US, where multiple-allergen mixes are routinely employed in SCIT, is the lack of evidence for efficacy of mixtures of more than two unrelated extracts⁷⁵.

In comparison with SLIT, there have been far fewer recent studies with SCIT. Most have reported on the development of products that offer greater convenience and safety over the use of SCIT with the currently available products. For the most part, these products are still under development. The exceptions are the allergoids, extracts modified by treatment with aldehydes, that in some cases have shown markedly reduced allergenicity, allowing very rapid build-up in dosing⁷⁶.

AIT has also been used in patients with LAR (see section on LAR above). Thirty-six subjects with perennial symptoms and positive NAPT to D. pt. received SCIT with D. pt. extract. At the end of 24 months, daily combined symptom/medication scores were reduced 42% compared with placebo ($P = 0.001$) and NAPT after one year showed markedly increased tolerance for D. pt. allergen⁷⁷. The same group also conducted a two-year trial of SCIT with a Timothy grass allergoid extract in 56 LAR subjects with positive NAPT to Timothy⁷⁸. In the first grass pollen season, after about six months of SCIT, combined symptom medication scores were reduced 54%. The efficacy of SCIT in pollen-induced LAR was also demonstrated in a two-year study in 28 subjects with birch sensitivity⁷⁹. The efficacy of SLIT in patients with LAR has not been reported.

Concluding remarks

There is no question that AR is a very common and often very burdensome disease. It can be classified as seasonal or perennial, which has the attraction of directing attention to

the relevant aeroallergen, or as intermittent and persistent and mild or moderate/severe that reflects more the burden of the disease on the patient. It is important not to confuse NAR with AR but also not to miss LAR if indeed it is as common as reports indicate. There is a need for more effective forms of symptomatic therapy⁸⁰. There also is a need for new approaches to AIT that overcome the factors of safety and inconvenience with SCIT but also the limited number of allergens with established dosing with SLIT. Both of these forms of AIT involve several years of treatment to produce lasting results and in many patients this leads to poor adherence with the treatment program⁸¹. Forms of AIT that require far fewer treatments over shorter periods of time are sorely needed.

Abbreviations

AIT, allergy immunotherapy; AR, allergic rhinitis; ARC, allergic rhinoconjunctivitis; ARIA, Allergic Rhinitis and its Impact on Asthma; CAM, complementary and alternative medicine; D. pt., *Dermatophagoides pteronyssinus*; FDA, US Food and Drug Administration; HDM, house dust mite; INSS, individual nasal symptom score; IR, idiopathic rhinitis; LAR, local allergic rhinitis; NAPT, nasal allergen provocation test; NAR, non-allergic rhinitis; PAR, perennial allergic rhinitis; PNAR, perennial non-allergic rhinitis; SAR, seasonal allergic rhinitis; SCIT, subcutaneous immunotherapy; sIgE, specific IgE; SLIT, sublingual immunotherapy; SR, systematic review; TRAE, treatment-related adverse event

Grant information

The author(s) declared that no grants were involved in supporting this work.

Acknowledgments

The authors wish to thank Diedre Versluis and Lien Hang for their assistance in preparing the manuscript.

References



1. **F** Meltzer EO: **Allergic Rhinitis: Burden of Illness, Quality of Life, Comorbidities, and Control.** *Immunol Allergy Clin North Am.* 2016; **36**(2): 235–48. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
2. Nathan RA, Meltzer EO, Derebery J, *et al.*: **The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey.** *Allergy Asthma Proc.* 2008; **29**(6): 600–8. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Bauchau V, Durham SR: **Prevalence and rate of diagnosis of allergic rhinitis in Europe.** *Eur Respir J.* 2004; **24**(5): 758–64. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Kurukulaaratchy RJ, Karmaus W, Raza A, *et al.*: **The influence of gender and atopy on the natural history of rhinitis in the first 18 years of life.** *Clin Exp Allergy.* 2011; **41**(6): 851–9. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Bielory L, Skoner DP, Blaiss MS, *et al.*: **Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) surveys.** *Allergy Asthma Proc.* 2014; **35**(3): 211–8. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Stuck BA, Czajkowski J, Hagner AE, *et al.*: **Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial.** *J Allergy Clin Immunol.* 2004; **113**(4): 663–8. [PubMed Abstract](#) | [Publisher Full Text](#)
7. **F** Dass K, Petrusan AJ, Beaumont J, *et al.*: **Assessment of sleep disturbance in children with allergic rhinitis.** *Ann Allergy Asthma Immunol.* 2017; **118**(4): 505–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
8. Ridolo E, Caffarelli C, Olivieri E, *et al.*: **Quality of sleep in allergic children and their parents.** *Allergol Immunopathol (Madr).* 2015; **43**(2): 180–4. [PubMed Abstract](#) | [Publisher Full Text](#)
9. **F** Vandenplas O, Vinnikov D, Blanc PD, *et al.*: **Impact of Rhinitis on Work Productivity: A Systematic Review.** *J Allergy Clin Immunol Pract.* 2018; **6**(4): 1274–1286.e9. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
10. Walker S, Khan-Wasti S, Fletcher M, *et al.*: **Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study.** *J Allergy Clin Immunol.* 2007; **120**(2): 381–7. [PubMed Abstract](#) | [Publisher Full Text](#)
11. **F** Cardell LO, Olsson P, Andersson M, *et al.*: **TOTAL: high cost of allergic rhinitis—a national Swedish population-based questionnaire study.** *NPJ Prim Care Respir Med.* 2016; **26**: 15082. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
12. Zuberbier T, Lötvall J, Simoons S, *et al.*: **Economic burden of inadequate management of allergic diseases in the European Union: A GA² LEN review.** *Allergy.* 2014; **69**(10): 1275–9. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Smith M, Cecchi L, Skjøth CA, *et al.*: **Common ragweed: a threat to environmental health in Europe.** *Environ Int.* 2013; **61**: 115–26. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Ziska L, Knowlton K, Rogers C, *et al.*: **Recent warming by latitude associated with increased length of ragweed pollen season in central North America.** *Proc Natl Acad Sci U S A.* 2011; **108**(10): 4248–51. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. **F** Lake IR, Jones NR, Agnew M, *et al.*: **Climate Change and Future Pollen Allergy in Europe.** *Environ Health Perspect.* 2017; **125**(3): 385–91. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. Papadopoulos NG, Bernstein JA, Demoly P, *et al.*: **Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report.** *Allergy.* 2015; **70**(5): 474–94. [PubMed Abstract](#) | [Publisher Full Text](#)
17. **F** Hellings PW, Klimek L, Cingi C, *et al.*: **Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology.** *Allergy.* 2017; **72**(11): 1657–65. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
18. **F** Papadopoulos NG, Guibas GV: **Rhinitis Subtypes, Endotypes, and Definitions.** *Immunol Allergy Clin North Am.* 2016; **36**(2): 215–33. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
19. Westman M, Stjærne P, Asarjov A, *et al.*: **Natural course and comorbidities of allergic and nonallergic rhinitis in children.** *J Allergy Clin Immunol.* 2012; **129**(2): 403–8. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Nihlén U, Greiff L, Montnémy P, *et al.*: **Incidence and remission of self-reported allergic rhinitis symptoms in adults.** *Allergy.* 2006; **61**(11): 1299–304. [PubMed Abstract](#) | [Publisher Full Text](#)
21. Bousquet J, Van Cauwenberge P, Khaltaev N: **Allergic rhinitis and its impact on asthma.** *J Allergy Clin Immunol.* 2001; **108**(5 Suppl): S147–334. [PubMed Abstract](#)
22. Bousquet J, Khaltaev N, Cruz AA, *et al.*: **Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).** *Allergy.* 2008; **63** Suppl 86: 8–160. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Brozek JL, Bousquet J, Baena-Cagnani CE, *et al.*: **Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.** *J Allergy Clin Immunol.* 2010; **126**(3): 466–76. [PubMed Abstract](#) | [Publisher Full Text](#)
24. Brozek JL, Bousquet J, Agache I, *et al.*: **Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision.** *J Allergy Clin Immunol.* 2017; **140**(4): 950–8. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Ciprandi G, Cirillo I, Vizzaccaro A, *et al.*: **Seasonal and perennial allergic rhinitis: Is this classification adherent to real life?** *Allergy.* 2005; **60**(7): 882–7. [PubMed Abstract](#) | [Publisher Full Text](#)
26. Rondón C, Romero JJ, López S, *et al.*: **Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis.** *J Allergy Clin Immunol.* 2007; **119**(4): 899–905. [PubMed Abstract](#) | [Publisher Full Text](#)
27. López S, Rondón C, Torres MJ, *et al.*: **Immediate and dual response to nasal challenge with *Dermatophagoides pteronyssinus* in local allergic rhinitis.** *Clin Exp Allergy.* 2010; **40**(7): 1007–14. [PubMed Abstract](#) | [Publisher Full Text](#)
28. Rondón C, Doña I, López S, *et al.*: **Seasonal idiopathic rhinitis with local inflammatory response and specific IgE in absence of systemic response.** *Allergy.* 2008; **63**(10): 1352–8. [PubMed Abstract](#) | [Publisher Full Text](#)
29. Rondón C, Campo P, Herrera R, *et al.*: **Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis.** *J Allergy Clin Immunol.* 2011; **128**(6): 1192–7. [PubMed Abstract](#) | [Publisher Full Text](#)
30. Rondón C, Campo P, Galindo L, *et al.*: **Prevalence and clinical relevance of local allergic rhinitis.** *Allergy.* 2012; **67**(10): 1282–8. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Buntarickpompnan P, Veskitkul J, Pacharn P, *et al.*: **The proportion of local allergic rhinitis to *Dermatophagoides pteronyssinus* in children.** *Pediatr Allergy Immunol.* 2016; **27**(6): 574–9. [PubMed Abstract](#) | [Publisher Full Text](#)
32. **F** Bozek A, Ignasiak B, Kasperska-Zajac A, *et al.*: **Local allergic rhinitis in elderly patients.** *Ann Allergy Asthma Immunol.* 2015; **114**(3): 199–202. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
33. Rondón C, Campo P, Zambonino MA, *et al.*: **Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis.** *J Allergy Clin Immunol.* 2014; **133**(4): 1026–31. [PubMed Abstract](#) | [Publisher Full Text](#)
34. **F** Rondon C, Campo P, Eguiluz-Gracia I, *et al.*: **Local allergic rhinitis is an independent rhinitis phenotype: The results of a 10-year follow-up study.** *Allergy.* 2018; **73**(2): 470–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20114S006_Astelin.cfm
36. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021861s000TOC.cfm
37. Kaliner MA, Storms W, Tilles S, *et al.*: **Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis.** *Allergy Asthma Proc.* 2009; **30**(3): 255–62. [PubMed Abstract](#) | [Publisher Full Text](#)
38. Berger W, Hampel F Jr, Bernstein J, *et al.*: **Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis.** *Ann Allergy Asthma Immunol.* 2006; **97**(3): 375–81. [PubMed Abstract](#) | [Publisher Full Text](#)
39. Drug Approval Package: **Omnaris (Ciclesonide) NDA #022004 [Internet].** U.S. Food and Drug Administration. 2006. [Reference Source](#)
40. Drug Approval Package: **Veramyst (fluticasone furoate) NDA #022051 [Internet].** U.S. Food and Drug Administration. 2007. [Reference Source](#)
41. Drug Approval Package: **Zetonna (ciclesonide) NDA #202129 [Internet].** U.S. Food and Drug Administration. 2012. [Reference Source](#)
42. Drug Approval Package: **Qnasl (beclomethasone dipropionate) NDA #202813 [Internet].** U.S. Food and Drug Administration. 2012. [Reference Source](#)
43. Drug Approval Package: **Dymista (azelastine hydrochloride and fluticasone propionate) NDA #202236 [Internet].** U.S. Food and Drug Administration. 2012. [Reference Source](#)
44. **Xhance (fluticasone propionate) Nasal Spray [Internet].** U.S. Food and Drug Administration. 2017. [Reference Source](#)

45. **F** Carr W, Bernstein J, Lieberman P, *et al.*: **A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis.** *J Allergy Clin Immunol.* 2012; **129**(5): 1282–1289.e10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
46. Hoyte FC, Meltzer EO, Ostrom NK, *et al.*: **Recommendations for the pharmacologic management of allergic rhinitis.** *Allergy Asthma Proc.* 2014; **35** Suppl 1: S20–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. **F** Brinkhaus B, Ortiz M, Witt CM, *et al.*: **Acupuncture in patients with seasonal allergic rhinitis: a randomized trial.** *Ann Intern Med.* 2013; **158**(4): 225–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
48. **F** Adam D, Grabenhenrich L, Ortiz M, *et al.*: **Impact of acupuncture on antihistamine use in patients suffering seasonal allergic rhinitis: secondary analysis of results from a randomised controlled trial.** *Acupunct Med.* 2018; **36**(3): 139–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
49. Xue CC, Zhang AL, Zhang CS, *et al.*: **Acupuncture for seasonal allergic rhinitis: a randomized controlled trial.** *Ann Allergy Asthma Immunol.* 2015; **115**(4): 317–324.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Taw MB, Reddy WD, Omole FS, *et al.*: **Acupuncture and allergic rhinitis.** *Curr Opin Otolaryngol Head Neck Surg.* 2015; **23**(3): 216–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. **F** Qiu J, Grine K: **Complementary and Alternative Treatment for Allergic Conditions.** *Prim Care.* 2016; **43**(3): 519–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
52. Kern J, Bielory L: **Complementary and alternative therapy (CAM) in the treatment of allergic rhinitis.** *Curr Allergy Asthma Rep.* 2014; **14**(12): 479.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. **F** Surda P, Fokkens WJ: **Novel, Alternative, and Controversial Therapies of Rhinitis.** *Immunol Allergy Clin North Am.* 2016; **36**(2): 401–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
54. **F** Nurmatov U, Dhami S, Arasi S, *et al.*: **Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic overview of systematic reviews.** *Clin Transl Allergy.* 2017; **7**: 24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. Durham SR, Yang WH, Pedersen MR, *et al.*: **Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.** *J Allergy Clin Immunol.* 2006; **117**(4): 802–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Didier A, Malling HJ, Worm M, *et al.*: **Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis.** *J Allergy Clin Immunol.* 2007; **120**(6): 1338–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Nolte H, Hébert J, Berman G, *et al.*: **Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.** *Ann Allergy Asthma Immunol.* 2013; **110**(6): 450–456.e4.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. **F** Creticos PS, Maloney J, Bernstein DI, *et al.*: **Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults.** *J Allergy Clin Immunol.* 2013; **131**(5): 1342–9.e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
59. **F** Demoly P, Emminger W, Rehm D, *et al.*: **Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.** *J Allergy Clin Immunol.* 2016; **137**(2): 444–451.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
60. Nayak AS, Atiee GJ, Dige E, *et al.*: **Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis.** *Allergy Asthma Proc.* 2012; **33**(5): 404–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Corzo JL, Carrillo T, Pedemonte C, *et al.*: **Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children.** *J Investig Allergol Clin Immunol.* 2014; **24**(3): 154–61.
[PubMed Abstract](#)
62. Nolte H, Bernstein DI, Kleine-Tebbe JR, *et al.*: **Efficacy and Safety of the SQ-House Dust Mite Sublingual Immunotherapy Tablet in North American Children and Adults: Findings from a Large Randomized, Placebo-Controlled Clinical Trial.** *J Allergy Clin Immunol.* 2016; **137**(2 Suppl): AB409.
[Publisher Full Text](#)
63. **F** Bergmann KC, Demoly P, Worm M, *et al.*: **Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis.** *J Allergy Clin Immunol.* 2014; **133**(6): 1608–14.e6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. **F** Okamoto Y, Fujieda S, Okano M, *et al.*: **House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis.** *Allergy.* 2017; **72**(3): 435–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
65. Nolte H, Casale TB, Lockey RF, *et al.*: **Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.** *J Allergy Clin Immunol Pract.* 2017; **5**(1): 84–89.e3.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Nolte H, Amar N, Bernstein DI, *et al.*: **Safety and tolerability of a short ragweed sublingual immunotherapy tablet.** *Ann Allergy Asthma Immunol.* 2014; **113**(1): 93–100.e3.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Durham SR, Emminger W, Kapp A, *et al.*: **SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.** *J Allergy Clin Immunol.* 2012; **129**(3): 717–725.e5.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Didier A, Malling HJ, Worm M, *et al.*: **Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score.** *Clin Transl Allergy.* 2015; **5**: 12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. **F** Scadding GW, Calderon MA, Shamji MH, *et al.*: **Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.** *JAMA.* 2017; **317**(6): 615–25.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
70. **F** Valovita E, Petersen TH, Piotrowska T, *et al.*: **Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy.** *J Allergy Clin Immunol.* 2018; **141**(2): 529–538.e13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
71. Tucker MH, Tankersley MS, ACAAI Immunotherapy and Diagnostics Committee: **Perception and practice of sublingual immunotherapy among practicing allergists.** *Ann Allergy Asthma Immunol.* 2008; **101**(4): 419–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Sikora JM, Tankersley MS, ACAAI Immunotherapy and Diagnostics Committee: **Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey.** *Ann Allergy Asthma Immunol.* 2013; **110**(3): 194–197.e4.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. **F** Larenas-Linnemann DE, Mösges R: **Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy.** *Allergy Asthma Proc.* 2016; **37**(1): 50–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
74. Moreno Benítez F, Espinazo Romeu M, Letrán Camacho A, *et al.*: **Variation in allergen content in sublingual allergen immunotherapy with house dust mites.** *Allergy.* 2015; **70**(11): 1413–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Amar SM, Harbeck RJ, Sills M, *et al.*: **Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.** *J Allergy Clin Immunol.* 2009; **124**(1): 150–156.e1-5.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Klimek L, Uhlig J, Mösges R, *et al.*: **A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.** *Allergy.* 2014; **69**(12): 1629–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. **F** Rondón C, Campo P, Salas M, *et al.*: **Efficacy and safety of *D. pteronyssinus* immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.** *Allergy.* 2016; **71**(7): 1057–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
78. **F** Rondón C, Blanca-López N, Campo P, *et al.*: **Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with *Pheum pratense* subcutaneous allergen immunotherapy.** *Allergy.* 2018; **73**(4): 905–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
79. **F** Bożek A, Kołodziejczyk K, Jarzab J: **Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis.** *Ann Allergy Asthma Immunol.* 2018; **120**(1): 53–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
80. Durham SR, Creticos PS, Nelson HS, *et al.*: **Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses.** *J Allergy Clin Immunol.* 2016; **138**(4): 1081–1088.e4.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. **F** Kiel MA, Röder E, van Gerth WR, *et al.*: **Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.** *J Allergy Clin Immunol.* 2013; **132**(2): 353–60.e2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Referee Status:  

Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

Version 1

- 1 **Cemal Cingi** ENT Department, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey
Competing Interests: No competing interests were disclosed.
- 2 **Miguel Blanca** Allergy Unit, Regional University Hospital of Malaga, Malaga, Spain
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research